Translate your project needs into precision-engineered diagnostic assays for diverse applications, including medicine, veterinary care, food industry, pharmaceuticals, industrial monitoring, environmental, and biodefense.
BioAssay Works has a a 20+ year proven track record of providing custom, turnkey lateral flow assay solutions for leading-edge companies.
January 2025
Ijamsville, MD
BioAssay Works LLC (BAW) announces the retirement of Stephen Mefferd, BAW’s co-founder and President. During the past 20 years at BAW, Stephen has been instrumental in leading the company from (more…)
October, 2024
Ijamsville, Maryland
BioAssay Works (BAW) further enhanced their assay development and manufacturing services capabilities by adding 1,000 square feet of R&D and manufacturing space. In addition, BAW acquired a new reel-to-reel membrane (more…)
November 11-14, 2024
Dusseldorf, Germany
Let BioAssay Works (BAW) help get your lateral flow assay to market faster. BAW specializes in developing lateral flow assays utilizing our deep expertise in gold nanoparticles. Our turnkey custom (more…)
The current U.S.-China trade war has reignited global concerns over the stability and security of supply chains — especially for critical sectors like diagnostics. For companies developing lateral flow assays and point-of-need tests, even small interruptions in material sourcing can result in delayed launches, failed partnerships, and lost revenue. (more…)
The global lateral flow assay (LFA) market is projected to reach $16.8 billion by 2029, driven by the need for point-of-care testing and early disease detection. The demand for fast, accurate, and accessible diagnostic testing has never been higher. (more…)